title: γδ T cells for cancer immunotherapy: A systematic review of clinical trials.
abstract: γδ T cells contribute to the front line of lymphoid antitumor surveillance and bridge the gap between innate and adaptive immunity. They can be readily expanded to high numbers in vivo and in vitro, starting from the blood of cancer patients, and a number of Phase I trials have demonstrated that these cells can be employed in cancer immunotherapy. Sufficient patients have received γδ T cell-based immunotherapies in the context of clinical trials to evaluate their utility, and to inform the direction of new trials. A systematic approach was used to identify Phase I, Phase II, and feasibility studies testing γδ T cell-based immunotherapy in cancer patients. Studies were excluded from further analysis if they did not provide patient-specific data. Data were compiled to evaluate efficacy, with stratification by treatment approach. When possible, comparisons were made with the efficacy of second-line conventional therapeutic approaches for the same malignancy. Twelve eligible studies were identified, providing information on 157 patients who had received γδ T cell-based immunotherapy. The comparison of objective response data suggests that γδ T cell-based immunotherapy is superior to current second-line therapies for advanced renal cell carcinoma and prostate cancer, but not for non-small cell lung carcinoma. An evaluation of pooled data from 132 published in vitro experiments shows a consistent improvement in the cytotoxicity of γδ T cells in the presence of antitumor antibodies. Immunotherapy using γδ T cells alone shows promising clinical activity, but there is a strong preclinical rationale for combining this treatment modality with cancer-targeting antibodies to augment its efficacy.
authors.affiliation: UCL Institute of Child Health; London, UK.
authors.forename: Jonathan Ph
authors.initials: JP
authors.lastname: Fisher
authors.affiliation: UCL Institute of Child Health; London, UK.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Heuijerjans
authors.affiliation: UCL Institute of Child Health; London, UK.
authors.forename: Mengyong
authors.initials: M
authors.lastname: Yan
authors.affiliation: UCL Institute of Child Health; Molecular Immunology Unit; London, UK.
authors.forename: Kenth
authors.initials: K
authors.lastname: Gustafsson
authors.affiliation: UCL Institute of Child Health; London, UK.
authors.forename: John
authors.initials: J
authors.lastname: Anderson
keywords: adoptive cell transfer; aminobisphosphonate; cancer; clinical trials; immunotherapy; systematic review; γδ T cell
references.citation: BMJ. 2008 Mar 15;336(7644):610-2
references.pmid: 18340076
references.citation: J Immunol. 1995 Apr 15;154(8):3932-40
references.pmid: 7706731
references.citation: Jpn J Clin Oncol. 2008 May;38(5):365-72
references.pmid: 18417502
references.citation: Immunology. 2009 Feb;126(2):256-67
references.pmid: 18775028
references.citation: Br J Cancer. 2011 Sep 6;105(6):778-86
references.pmid: 21847128
references.citation: J Immunol. 2009 Nov 1;183(9):5622-9
references.pmid: 19843947
references.citation: Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6222s-6230s
references.pmid: 17062705
references.citation: Cancer Immunol Immunother. 2008 Nov;57(11):1599-609
references.pmid: 18301889
references.citation: Expert Opin Biol Ther. 2013 Feb;13(2):303-13
references.pmid: 23265575
references.citation: Cancer Immunol Immunother. 2011 Oct;60(10):1447-60
references.pmid: 21647691
references.citation: J Clin Oncol. 1999 Jul;17(7):2105-16
references.pmid: 10561265
references.citation: Exp Hematol. 2009 Aug;37(8):956-68
references.pmid: 19409955
references.citation: J Immunother. 2012 Feb-Mar;35(2):205-13
references.pmid: 22306909
references.citation: Lancet Oncol. 2013 Sep;14(10):981-8
references.pmid: 23883922
references.citation: J Immunother. 2000 Jan;23(1):154-60
references.pmid: 10687148
references.citation: N Engl J Med. 1988 Dec 22;319(25):1676-80
references.pmid: 3264384
references.citation: J Exp Med. 2003 Jan 20;197(2):163-8
references.pmid: 12538656
references.citation: Cell Mol Immunol. 2012 Jan;9(1):34-44
references.pmid: 21666706
references.citation: Nat Rev Cancer. 2012 Mar 22;12(4):265-77
references.pmid: 22437871
references.citation: Blood. 2011 Sep 15;118(11):3019-27
references.pmid: 21816829
references.citation: Cytotherapy. 2008;10(8):842-56
references.pmid: 19016372
references.citation: Br J Haematol. 2013 Jan;160(2):123-32
references.pmid: 23061882
references.citation: N Engl J Med. 2010 Aug 19;363(8):711-23
references.pmid: 20525992
references.citation: Cell Mol Immunol. 2013 Jan;10(1):35-41
references.pmid: 23241899
references.citation: J Clin Pharmacol. 2003 Feb;43(2):154-62
references.pmid: 12616668
references.citation: Cancer Immunol Immunother. 2010 Oct;59(10):1521-30
references.pmid: 20563721
references.citation: Blood. 2009 May 14;113(20):4875-84
references.pmid: 19278954
references.citation: Cytotherapy. 2013 Apr;15(4):481-91
references.pmid: 23391461
references.citation: Clin Exp Immunol. 2010 Aug;161(2):290-7
references.pmid: 20491785
references.citation: Eur J Immunol. 2009 Mar;39(3):752-62
references.pmid: 19197941
references.citation: J Clin Oncol. 1995 Mar;13(3):688-96
references.pmid: 7884429
references.citation: Blood. 2000 Jul 15;96(2):384-92
references.pmid: 10887096
references.citation: Cancer Lett. 2005 Oct 18;228(1-2):155-61
references.pmid: 15923080
references.citation: Blood. 1994 Aug 1;84(3):964-71
references.pmid: 8043878
references.citation: J Clin Oncol. 2008 Nov 10;26(32):5261-8
references.pmid: 18794543
references.citation: Eur J Cancer. 1994;30A(8):1078-83
references.pmid: 7654433
references.citation: J Clin Oncol. 2007 Jun 20;25(18):2586-93
references.pmid: 17577038
references.citation: Blood. 2009 Jul 9;114(2):310-7
references.pmid: 19436053
references.citation: Cancer Lett. 2003 Jul 18;197(1-2):205-9
references.pmid: 12880983
references.citation: Int J Cancer. 2010 Jan 1;126(1):239-46
references.pmid: 19621390
references.citation: PLoS One. 2013 May 07;8(5):e62847
references.pmid: 23667530
references.citation: Lung Cancer. 2011 Nov;74(2):274-9
references.pmid: 21439671
references.citation: J Immunol. 2012 Feb 15;188(4):1708-16
references.pmid: 22250090
references.citation: Immunity. 2009 Aug 21;31(2):184-96
references.pmid: 19699170
references.citation: J Neurosci. 2005 Mar 9;25(10):2537-46
references.pmid: 15758163
references.citation: Haematologica. 2011 Mar;96(3):400-7
references.pmid: 21109686
references.citation: Int J Cancer. 2008 Jun 1;122(11):2526-34
references.pmid: 18307255
references.citation: Cancer. 2010 Sep 15;116(18):4256-65
references.pmid: 20549832
references.citation: Lancet. 2010 Dec 11;376(9757):1989-99
references.pmid: 21131037
references.citation: Cancer Immunol Immunother. 2011 Aug;60(8):1075-84
references.pmid: 21519826
references.citation: Eur J Immunol. 2012 Jul;42(7):1668-76
references.pmid: 22806069
references.citation: Nat Med. 2004 Sep;10(9):942-9
references.pmid: 15322536
references.citation: Anticancer Res. 2004 May-Jun;24(3b):1861-71
references.pmid: 15274367
references.citation: J Immunol. 2011 Jul 15;187(2):1031-8
references.pmid: 21670311
references.citation: Eur J Cardiothorac Surg. 2010 May;37(5):1191-7
references.pmid: 20137969
references.citation: Eur J Immunol. 2007 Jul;37(7):1864-73
references.pmid: 17557374
references.citation: Clin Cancer Res. 2011 Jul 1;17(13):4550-7
references.pmid: 21498393
references.citation: PLoS One. 2013 May 22;8(5):e64936
references.pmid: 23717676
references.citation: J Immunother. 2010 Jul-Aug;33(6):591-8
references.pmid: 20551838
references.citation: Blood. 2003 Jul 1;102(1):200-6
references.pmid: 12623838
references.citation: Nat Rev Immunol. 2013 Feb;13(2):88-100
references.pmid: 23348415
references.citation: Cancer Res. 2007 Aug 1;67(15):7450-7
references.pmid: 17671215
references.citation: J Immunother. 2012 Jul;35(6):449-59
references.pmid: 22735803
references.citation: Eur Rev Med Pharmacol Sci. 2011 Mar;15(3):325-31
references.pmid: 21528780
references.citation: Immunol Lett. 2009 May 14;124(1):1-8
references.pmid: 19465238
references.citation: Clin Immunol. 2008 Aug;128(2):219-27
references.pmid: 18501678
references.citation: Science. 2005 Jul 8;309(5732):264-8
references.pmid: 15933162
references.citation: Cancer Res. 2011 Jul 1;71(13):4562-72
references.pmid: 21646473
references.citation: N Engl J Med. 2011 Dec 1;365(22):2055-66
references.pmid: 22129252
references.citation: J Immunother. 2011 Mar;34(2):202-11
references.pmid: 21304399
references.citation: Mol Biol Rep. 2013 Jan;40(1):427-37
references.pmid: 23065272
references.citation: Cancer J Sci Am. 2000 Feb;6 Suppl 1:S52-4
references.pmid: 10685659
references.citation: Br J Haematol. 2007 Oct;139(2):206-16
references.pmid: 17897296
references.citation: J Clin Invest. 2007 May;117(5):1167-74
references.pmid: 17476346
references.citation: J Clin Invest. 2001 Nov;108(9):1349-57
references.pmid: 11696580
references.citation: Cell Mol Life Sci. 2011 Jul;68(14):2443-52
references.pmid: 21573785
references.citation: Cancer Immunol Immunother. 2007 Apr;56(4):469-76
references.pmid: 16850345
references.citation: N Engl J Med. 2013 Jul 11;369(2):134-44
references.pmid: 23724846